We extend our deepest gratitude to Dr. Jennifer Guy, Dr. Anjana Pillai, Dr. Christopher Rose, Dr. Elliot Tapper, patient advocate Bruce Dimming, and our sponsors. In case you missed it, our webinar ‘Liver Cancer Care: Management of Hepatic Encephalopathy, Ascites, and Portal Hypertension’ is available on GLI’s YouTube channel! Whether you’re a patient, caregiver, or healthcare professional, this webinar offers guidance and education to improve liver care.
Global Liver Institute
GLOBAL LIVER INSTITUTE
Global Liver Institute Statement on the Passing of Dr. Stephen Harrison
The entire field of liver health has experienced an incredible loss. It is with great sadness that Global Liver Institute, our Liver Action Network members and the patient community express our deepest sorrow on the sudden passing of Dr Stephen Harrison. Our condolences and prayers are with Dr. Harrison’s family, friends and loved ones.
Addressing Disparities in Organ Transplantation: A Call for Equitable Healthcare
Organ transplantation has revolutionized modern medicine, offering a beacon of hope for individuals battling end-stage organ failure. At the same time, it is intricately entwined with legal and policy frameworks governing procurement, allocation, and ethical considerations. From national regulations to international collaborations, addressing healthcare disparities and combating systemic injustices are vital to providing equal access to lifesaving procedures.
Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients.
After a brief weekend shutdown, Congress passed the FY 2024 appropriations bills and President Joe Biden signed the $1.2 trillion government funding package on March 23, 2024, closing the books on fiscal year (FY) 2024 appropriations.
Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News
Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).
GLI Celebrates US Treatment for NASH as Milestone for Liver Health – NASH News
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.
NIH Launches Research Network To Evaluate Emerging Cancer Screening Technologies – Liver Cancer News
This landmark announcement from the White House follows ongoing advocacy efforts, including a letter to President Joe Biden sent by Prevent Cancer Foundation, GLI, and 80 other advocacy groups to establish Cancer Prevention and Early Detection Month.
Healthy Eating, Healthy Liver: The Links Between Nutrition and Liver Wellness
Maintaining optimal liver health is crucial, given the liver’s pivotal role as a major detoxifying organ. The liver, being a primary filter of toxins and chemicals that pass through the body, is influenced by an individual’s dietary choices.
Media Kit: Preparing for First US Approval of NASH Therapy
Our press kit explains the core facts of the GLI, the Resmetirom launch, and why it’s important (especially to patients) to journalists/reporters/the media in a neat, digestible package.
7th Annual Global Fatty Liver Day is less than 3 months away!
Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It impacts millions worldwide leading to missed opportunities for early intervention and prevention. Studies highlight a concerning gap in identifying patients within the healthcare system who may have fatty liver disease unknowingly. We cannot afford to overlook the silent nature of this and this is why we are advocating for immediate action.
GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC
(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the breaking news of the U.S. FDA’s approval for Mirum Pharmaceuticals’ Livmarli to treat cholestasis pruritus in patients 5 and older that have been diagnosed with progressive familial intrahepatic cholestasis (PFIC), a rare, genetic disorder in which bile builds up in the liver.
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication for nonalcoholic steatosis (NASH). Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.